The Show Must Go On

An Update on Clinical Experiences and Clinical Studies on Novel Pharmaceutical Developments for the Treatment of Atopic Dermatitis

Tatjana Honstein; Thomas Werfel


Curr Opin Allergy Clin Immunol. 2020;20(4):386-394. 

In This Article

Targeting the Phospodiesterase-4 Receptor for the Topical Treatment of Atopic Dermatitis With Crisaborole

Crisaborole is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. In two pivotal phase III clinical trials in patients aged at least 2 years, crisaborole was superior to vehicle in reducing global disease severity.[59] A crisaborole cream was approved by the FDA for the treatment of atopic dermatitis but not by the EMA so far. The most common treatment-related adverse event is application site pain. In a recent study, the relationship between pruritus and quality of life was quantified using data from the phase III studies with crisaborole.[60] A clear relationship between the Severity of Pruritus Scale SPS, the Dermatology Life Quality Index DLQI, the Children's Dermatology Life Quality Index CDLQI and the Dermatitis Family Impact DFI was shown with these clinical data. Moreover, an independent recent pooled post hoc analysis by race and ethnicity of the two pivotal phase III trials. Across races and ethnicities, crisaborole demonstrated efficacy for the treatment of mild-to-moderate atopic dermatitis, with a low frequency of treatment-related adverse events.[61]